Back

Optimizing beta-blocker dosage in female patients using the wearable cardioverter defibrillator: the OPT-BB Women interventional study

11 May 2026 (13:30 - 14:15)
Organised by: Logo
Congress Presentation Part of: Evolving electrophysiological therapies: implantable cardioverter-defibrillator and cardiac resynchronisation therapy Pharmacotherapy HFA Premium Access Heart Failure 2026 Heart Failure Association (HFA)

About the speaker

Photo
Professor Valentina Kutyifa

University of Rochester, Rochester (United States of America)

5 More presentations in this session

Presentation thumbnail
Novel echocardiography-derived haemodynamic forces analysis in cardiac resynchronization therapy: response prediction and long-term prognosis
Doctor R. Tarantini (Utrecht, NL)
Abstract Slides
Presentation thumbnail
Cardiac resynchronization therapy outcomes by patient sex and baseline QRS duration: insights from AdaptResponse
Doctor B. Gerritse (Maastricht, NL)
Abstract Slides Video
Presentation thumbnail
Refining patient selection for CRT: the role of true LBBB morphology in CRT response
Doctor J. Simoes De Azevedo Massa Pereira (Faro, PT)
Abstract Slides Video
Presentation thumbnail
Frontal QRS-T angle identifies non-responders to cardiac resynchronisation therapy even among ideal candidates with heart failure
Doctor B. Yencilek (Ankara, TR)
Abstract Slides Video
Presentation thumbnail
Appropriate device therapies after CRT-D implantation in the modern heart failure treatment era
Doctor I. Martins Moreira (Vila Real, PT)
Abstract Slides Video

Access the full session

Session thumbnail
Evolving electrophysiological therapies: implantable cardioverter-defibrillator and cardiac resynchronisation therapy

The Event

Event poster

Heart Failure 2026

11 May 2026 13:30 CET
You may be interested in
thumbnail
Congress Presentation
Adequately Beta-blocked? Insights from longitudinal wearable data in the All of Us Research Program
thumbnail
Congress Presentation
Wearable cardioverter-defibrillator compared to beta blockers in patients at risk of sudden death: a real-world propensity score-matched study.
thumbnail
Congress Session
Smaller trials, trial updates, and other studies on heart failure (1)

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources